A retrospective review of 1,438 patients in New York hospitalized for COVID-19 infection found no difference for in-hospital mortality with hydroxychloroquine, azithromycin, or both compared to not receiving either drug.
In a 21-day, 45 patient, non-randomized, observational trial, the addition of anakinra to hydroxychloroquine and lopinavir/ritonavir reduced serum C-reactive protein and improved respiratory function in 72% of patients compared to 50% in a historical cohort that had not received anakinra in patients with moderate-to-severe ARDS from COVID-19 that were managed with non-invasive ventilation outside of the ICU. Survival was 90% with anakinra and 50% without the drug at 21 days.
In a 21 patient, Chinese, uncontrolled retrospective study of patients with severe or critical COVID-19, tocilizumab was added after 7-days of standard treatment. At the time of the study, standard treatment was lopinavir/ritonavir, interferon, ribavirin and glucocorticoids. Fevers and elevated C-reactive protein levels normalized, and levels of IL-6 and other proinflammatory cytokines declined within 24 hours of tocilizumab administration. Within the first 5-days, there was a decrease in the use of supplemental oxygen in 15 patients.
The Russian Direct Investment Fund announced interim results from a 330 patient Russian trial, where 24/40 (60%) of patients treated with favipiravir were negative for COVID-19 within five days compared to 30% in the standard therapy group. The press release did not specify how many patients were in the standard care group, how patients were tested for COVID-19, nor what other therapies are part of standard care for COVID-19 in Russia. The trial is expected to be completed by the end of May 2020.
The FDA granted Moderna’s COVID-19 vaccine (mRNA-1273) a Fast Track designation.
NIH has formed the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership with HHS, FDA, CDC, EMA and AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Evotec, GlaxoSmithKline, J&J, KSQ Therapeutics, Eli Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda and Vir. ACTIV will coordinate and prioritize trials to optimize vaccine and treatment development for COVID-19 through a steering committee of representatives of members.
Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker